Unfortunately, prostate cancer cells eventually develop the ability to activate AR independently of androgen and patients invariably develop the more aggressive castration-resistant prostate cancer (CRPC), which is associated with a much worse prognosis [4–6]. This evidence concerns the gene AR and prostate cancer.